Company
Galecto Biotech
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Galecto Biotech develops new therapies for fibrotic diseases and inflammation based on inhibition of Galectins.
The Company is based on seminal research from Lund University, Sweden, exploring the role of a group of proteins called Galectins. The lead program is in late stage clinical development and addresses a novel therapeutic target for Ideopatic Pulmonary Fibrosis called Galectin-3. Additional programs targets other fibrotic diseases. Galecto listed
Funding snapshot
- Latest round
- Series C2018-10-26
Funding rounds
- Series C
- 2018-10-26
Loading relationship preview